Long-Term Outcomes of Neoadjuvant Immunotherapy in Lung Cancer Patients Comparing Surgery and Non-Surgical Treatments

What this Trial Is About

Researchers are studying the long-term effects of neoadjuvant immunotherapy in patients with non-small cell lung cancer. This observational study aims to determine if pneumonectomy offers more benefits than lobectomy, and whether surgery provides greater advantages compared to non-surgical treatments such as radiotherapy after neoadjuvant immunotherapy. The goal is to improve clinical decision-making and patient care by analyzing these treatment approaches. Participants will have received neoadjuvant immunotherapy before entering the study. Some will undergo surgery, either pneumonectomy or lobectomy, while others will receive non-surgical treatments like radiotherapy or anti-tumor drugs after their initial immunotherapy. The study will observe and compare these treatment paths without assigning interventions. During the study, participants health and treatment outcomes will be monitored, including event-free survival, defined as time from neoadjuvant treatment to metastasis or death, tracked for up to about 10 years. Other measures include overall survival and perioperative complication rates within six months after neoadjuvant therapy. The study involves collecting clinical data, imaging, and monitoring participants over the long term to understand the effects of these treatments.

Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer